EDDING GENOR Shares Rise Nearly 4% Following Preclinical Data Release of EDP001 at 2026 AACR Conference

Stock News04-23

EDDING GENOR (06998) saw an increase of nearly 4%, reaching a gain of 3.34% to HK$3.4 by the time of writing, with a trading volume of HK$5.134 million. On April 22, the company announced via its official social media account that preclinical research data for its highly innovative tetra-specific T-cell engager EDP001 (CD3/CD19/CD19/BCMA) were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Preclinical studies demonstrated that EDP001 exhibits potent in vitro cell-killing ability, significant in vivo tumor growth inhibition, and low cytokine secretion levels. These findings indicate that EDP001 holds promising clinical application potential in B-cell lymphoma and B-cell-related autoimmune diseases. EDP001 is a cutting-edge innovative product independently developed on EDDING GENOR's large-molecule antibody drug R&D platform, targeting the high-potential fields of autoimmune diseases and B-cell lymphoma. The platform focuses on advanced molecular formats such as bispecific/multispecific antibodies, T-cell engagers, and antibody-drug conjugates, and has established end-to-end capabilities from target discovery to drugability assessment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment